ProCE Banner Activity

HIMALAYA: Patient-Reported Outcomes for Patients With Unresectable Hepatocellular Carcinoma Receiving Durvalumab ± Tremelimumab

Slideset Download
Conference Coverage
Compared with sorafenib treatment alone, addition of a single dose of tremelimumab to durvalumab in STRIDE and durvalumab monotherapy were associated with meaningful, patient-centered benefits for patients with unresectable hepatocellular carcinoma.

Released: June 06, 2022

Expiration: June 05, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab